"
Team:UT-Dallas/Project
From 2014.igem.org
(Difference between revisions)
| (26 intermediate revisions not shown) | |||
| Line 1: | Line 1: | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
<html> | <html> | ||
| - | + | <link rel="stylesheet" href="https://2014.igem.org/Team:UT-Dallas/style-css?action=raw&ctype=text/css"> | |
| - | < | + | <link rel="stylesheet" href="https://2014.igem.org/Team:UT-Dallas/tooltipster.css?action=raw&ctype=text/css"> |
| - | + | <link rel="stylesheet" href="https://2014.igem.org/Team:UT-Dallas/dropit.css?action=raw&ctype=text/css"> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/TweenMax.min.js?action=raw&ctype=text/javascript"></script> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/jquery.js?action=raw&ctype=text/javascript"></script> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/jquery.scrollmagic.min.js?action=raw&ctype=text/javascript"></script> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/jquery.tooltipster.min.js?action=raw&ctype=text/javascript"></script> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/dropit.js?action=raw&ctype=text/javascript"></script> | |
| - | + | <div id="content_body"> | |
| - | + | <section id="titlechart"></html>{{Header_menu}}<html><div class="page_content"><br><h2>Introduction</H2><p style="display:block"> | |
| - | + | We envision a new paradigm for treating infections of the human gastrointestinal tract through exploitation of engineered probiotics that produce anti-microbials with high specificity for pathogens. The anti-microbials we are exploring do not utilize a one-fit all therapy mold, but target unique features specific to organisms at the genetic level. Towards this aim, we have utilized a general-purpose system that will be delivered to pathogenic bacteria from an engineered bacterial species found in the GI tract (Escherichia coli), which will cleave pathogenic genes with single nucleotide resolution. To achieve specific genome targeting, we will utilize the CRISPR/Cas9 system with gRNA engineered to recognize genes from infectious bacteria that contribute to pathogenicity in humans. Our CRISPR/Cas9 system will be delivered from the engineered E. coli to infectious bacteria using bacterial specific phages, minimizing any side-effects to native microbiota and human-host cells. As a proof-of-principle for our engineered probiotic, we are starting by targeting Vibrio cholerae, however we hope to expand the system to other pathogens of the GI tract. | |
| - | + | </p><br><br> | |
| - | + | </div> | |
| - | + | </section> | |
| - | + | <section class="demo"> | |
| - | + | <div id="trigger1" class="spacer s0"></div> | |
| - | + | <div id="parallax1" class="spacer s2" style="background-image: url(https://static.igem.org/mediawiki/2014/1/19/UTD_Lab.jpg);"></div> | |
| - | + | <div class="spacer s1"> | |
| - | + | <div class="page_content"> | |
| - | + | <br><h2>Probiotics</H2><br><p style="display:block"> | |
| - | + | <br><br> | |
| - | + | Once complete, our system will be able to remain as a stable population in a person’s gut until the event of a V. cholerae infection. Detection of V. cholerae will then activate production of the phage delivery system, which will package the gRNA and Cas9 targeting system into a phage coat, exit the probiotic and transfer the system into V. cholerae present in the gut (transmission of a heterologous DNA message via phage was demonstrated by Ortiz and Endy in 2012 and featured in Waterloo’s 2013 iGEM project (2)). Once inside V. cholerae, the targeting system will bind and cleave sites complementary to the gRNA that correspond to selected pathogenicity genes. We proposed using Cas9/gRNA to target and kill pathogens as opposed to traditional phage therapy using a targeted lytic phage because it allowed us to differentiate and kill harmful pathogens of a strain that has both harmful and harmless serotypes. The gRNA in our system, while specific to V. cholerae, can easily be altered with PCR to target unique regions in other gastrointestinal pathogens. | |
| - | + | </p><br><br> | |
| - | + | </div> | |
| - | + | </div> | |
| - | + | <div id="trigger2" class="spacer s0"></div> | |
| - | + | <div id="parallax2" class="spacer s2" style="background-image: url(https://static.igem.org/mediawiki/2014/c/cb/Lab2.jpg);"></div> | |
| - | + | <div class="spacer s1"> | |
| - | < | + | <div class="page_content"> |
| - | + | <br><h2>References</H2><br><p style="display:block"> | |
| - | + | 1. Sinclair D., Abba K., Zaman K., Qadri F., Graves P.M., Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD008603.<br> | |
| - | < | + | 2. Ortiz M.E., Endy D. Engineered cell-cell communication via DNA messaging. J Biol Eng. 2012 Sep 7;6(1):16.</p><br><br> |
| - | + | </div> | |
| - | + | </div> | |
| - | + | <div id="trigger3" class="spacer s0"></div> | |
| - | + | <div id="parallax3" class="spacer s2" style="background-image: url(https://static.igem.org/mediawiki/2014/b/b8/Team.jpg);"></div> | |
| - | + | <div class="spacer s2"></div> | |
| - | + | <script src="https://2014.igem.org/Team:UT-Dallas/general.js?action=raw&ctype=text/javascript"></script> | |
| - | < | + | </section> |
| - | + | </div> | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | < | + | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | We envision a new paradigm for treating infections of the human gastrointestinal tract through exploitation of engineered probiotics that produce anti-microbials with high specificity for pathogens. The anti-microbials we are exploring do not utilize a one-fit all therapy mold, but target unique features specific to organisms at the genetic level. Towards this aim, we have utilized a general-purpose system that will be delivered to pathogenic bacteria from an engineered bacterial species found in the GI tract (Escherichia coli), which will cleave pathogenic genes with single nucleotide resolution. To achieve specific genome targeting, we will utilize the CRISPR/Cas9 system with gRNA engineered to recognize genes from infectious bacteria that contribute to pathogenicity in humans. Our CRISPR/Cas9 system will be delivered from the engineered E. coli to infectious bacteria using bacterial specific phages, minimizing any side-effects to native microbiota and human-host cells. As a proof-of-principle for our engineered probiotic, we are starting by targeting Vibrio cholerae, however we hope to expand the system to other pathogens of the GI tract. | + | |
| - | + | ||
| - | <br> | + | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | </ | + | |
| - | + | ||
| - | < | + | |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | < | + | |
| - | + | ||
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | < | + | |
| - | </ | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </ | + | |
</html> | </html> | ||
Latest revision as of 01:33, 18 October 2014
Introduction
We envision a new paradigm for treating infections of the human gastrointestinal tract through exploitation of engineered probiotics that produce anti-microbials with high specificity for pathogens. The anti-microbials we are exploring do not utilize a one-fit all therapy mold, but target unique features specific to organisms at the genetic level. Towards this aim, we have utilized a general-purpose system that will be delivered to pathogenic bacteria from an engineered bacterial species found in the GI tract (Escherichia coli), which will cleave pathogenic genes with single nucleotide resolution. To achieve specific genome targeting, we will utilize the CRISPR/Cas9 system with gRNA engineered to recognize genes from infectious bacteria that contribute to pathogenicity in humans. Our CRISPR/Cas9 system will be delivered from the engineered E. coli to infectious bacteria using bacterial specific phages, minimizing any side-effects to native microbiota and human-host cells. As a proof-of-principle for our engineered probiotic, we are starting by targeting Vibrio cholerae, however we hope to expand the system to other pathogens of the GI tract.
Probiotics
Once complete, our system will be able to remain as a stable population in a person’s gut until the event of a V. cholerae infection. Detection of V. cholerae will then activate production of the phage delivery system, which will package the gRNA and Cas9 targeting system into a phage coat, exit the probiotic and transfer the system into V. cholerae present in the gut (transmission of a heterologous DNA message via phage was demonstrated by Ortiz and Endy in 2012 and featured in Waterloo’s 2013 iGEM project (2)). Once inside V. cholerae, the targeting system will bind and cleave sites complementary to the gRNA that correspond to selected pathogenicity genes. We proposed using Cas9/gRNA to target and kill pathogens as opposed to traditional phage therapy using a targeted lytic phage because it allowed us to differentiate and kill harmful pathogens of a strain that has both harmful and harmless serotypes. The gRNA in our system, while specific to V. cholerae, can easily be altered with PCR to target unique regions in other gastrointestinal pathogens.
References
1. Sinclair D., Abba K., Zaman K., Qadri F., Graves P.M., Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD008603.
2. Ortiz M.E., Endy D. Engineered cell-cell communication via DNA messaging. J Biol Eng. 2012 Sep 7;6(1):16.
